form
liquid
Quality Level
manufacturer/tradename
Novagen®
storage condition
OK to freeze
storage temp.
−70°C
General description
The pRSF-1b plasmid features coexpression capabilities as well as the ability to express fusion proteins with a N-terminal His•Tag coding sequence that results in native protein after purification and cleavage. This plasmid carries an origin derived from RSF1030 (1, 2) and kanamycin resistance, allowing for the option of coexpression with many other Novagen T7-based expression vectors. Please read technical bulletin, TB401, for all possibilities and contact technical service if you need additional information.
This plasmid contains a strong T7lac promoter, an amino-terminal His•Tag coding sequence, and multiple cloning site (MCS) regions designed to allow the generation of target proteins with minimal vector encoded fusion. The Pml I cloning site allows direct fusion to the His•Tag sequence for inserts that are blunt and in the appropriate reading frame. For applications requiring a removable amino-terminal His•Tag sequence, the MCS includes a PshA I cloning site (GACNNNNGTC). The PshA I site overlaps the cleavage site for the enterokinase (EK) protease (AspAspAspAspLys). Cloning appropriately designed inserts into this site re-creates the full EK site and allows all amino-terminal vector-encoded sequences to be removed by EK digestion. The remainder of the MCS encodes restriction enzyme sites found in many other Novagen expression vectors to facilitate insert transfer. An optional S•Tag coding sequence is present at the distal end of the MCS for generating a carboxy-terminal tag compatible with purification, detection, and quantification (3).
This plasmid contains a strong T7lac promoter, an amino-terminal His•Tag coding sequence, and multiple cloning site (MCS) regions designed to allow the generation of target proteins with minimal vector encoded fusion. The Pml I cloning site allows direct fusion to the His•Tag sequence for inserts that are blunt and in the appropriate reading frame. For applications requiring a removable amino-terminal His•Tag sequence, the MCS includes a PshA I cloning site (GACNNNNGTC). The PshA I site overlaps the cleavage site for the enterokinase (EK) protease (AspAspAspAspLys). Cloning appropriately designed inserts into this site re-creates the full EK site and allows all amino-terminal vector-encoded sequences to be removed by EK digestion. The remainder of the MCS encodes restriction enzyme sites found in many other Novagen expression vectors to facilitate insert transfer. An optional S•Tag coding sequence is present at the distal end of the MCS for generating a carboxy-terminal tag compatible with purification, detection, and quantification (3).
Warning
Toxicity: Standard Handling (A)
Other Notes
1. Som, T. and Tomizawa, J. (1982) Mol. Gen. Genet.187, 375–383.
2. Cannon, P.M. and Strike, P. (1992) Plasmid27, 220–230.
3. Kim, J.S. and Raines, R.T. (1993) Protein Science2, 348–356.
2. Cannon, P.M. and Strike, P. (1992) Plasmid27, 220–230.
3. Kim, J.S. and Raines, R.T. (1993) Protein Science2, 348–356.
Legal Information
NOVAGEN is a registered trademark of Merck KGaA, Darmstadt, Germany
Storage Class Code
10 - Combustible liquids
WGK
WGK 1
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service